MX355177B - Composicion farmaceutica de avidina oxidada adecuada para inhalacion. - Google Patents
Composicion farmaceutica de avidina oxidada adecuada para inhalacion.Info
- Publication number
- MX355177B MX355177B MX2014001176A MX2014001176A MX355177B MX 355177 B MX355177 B MX 355177B MX 2014001176 A MX2014001176 A MX 2014001176A MX 2014001176 A MX2014001176 A MX 2014001176A MX 355177 B MX355177 B MX 355177B
- Authority
- MX
- Mexico
- Prior art keywords
- inhalation
- oxidised
- pharmaceutical composition
- avidin
- avidin suitable
- Prior art date
Links
- 108090001008 Avidin Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11006338 | 2011-08-02 | ||
| PCT/EP2012/064576 WO2013017494A1 (en) | 2011-08-02 | 2012-07-25 | Pharmaceutical composition of oxidised avidin suitable for inhalation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014001176A MX2014001176A (es) | 2014-07-14 |
| MX355177B true MX355177B (es) | 2018-04-09 |
Family
ID=46581966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014001176A MX355177B (es) | 2011-08-02 | 2012-07-25 | Composicion farmaceutica de avidina oxidada adecuada para inhalacion. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9872831B2 (enExample) |
| EP (1) | EP2739314B1 (enExample) |
| JP (1) | JP6019118B2 (enExample) |
| KR (1) | KR101966630B1 (enExample) |
| CN (1) | CN103717239B (enExample) |
| AU (1) | AU2012292229B2 (enExample) |
| BR (1) | BR112014002593B1 (enExample) |
| CA (1) | CA2842276C (enExample) |
| DK (1) | DK2739314T3 (enExample) |
| EA (1) | EA026453B1 (enExample) |
| ES (1) | ES2729549T3 (enExample) |
| IL (1) | IL230597A0 (enExample) |
| MX (1) | MX355177B (enExample) |
| PH (1) | PH12014500193A1 (enExample) |
| PL (1) | PL2739314T3 (enExample) |
| PT (1) | PT2739314T (enExample) |
| UA (1) | UA114482C2 (enExample) |
| WO (1) | WO2013017494A1 (enExample) |
| ZA (1) | ZA201401921B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016511747A (ja) | 2013-01-04 | 2016-04-21 | マサチューセッツ インスティテュート オブ テクノロジー | ナノ粒子表面結合に基づく薬物の組織への送達 |
| WO2017201436A1 (en) * | 2016-05-19 | 2017-11-23 | University Of Miami | Targeted delivery of therapeutic agents and imaging reagents to pancreatic cancer cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5384128A (en) * | 1993-03-02 | 1995-01-24 | University Of Alabama Research Foundation | Method of and compounds for treatment for cystic fibrosis |
| NZ271181A (en) | 1993-07-19 | 1998-06-26 | Amgen Inc | Protein protection; method for stabilising aerosolised proteins by adding a water-soluble polar organic compound to the aqueous solution prior to aerosolisation |
| NZ337924A (en) * | 1997-02-20 | 2002-09-27 | Klaus Kimmeldirk | Site-specific drug delivery compounds comprising an anchoring moiety, a linking group and a drug |
| AU779869B2 (en) * | 1999-04-13 | 2005-02-17 | Nektar Therapeutics | Pulmonary administration of dry powder formulations for treating infertility |
| US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| ITRM20010079A1 (it) | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
| ITRM20030196A1 (it) * | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
| EP2311793A1 (en) * | 2004-12-17 | 2011-04-20 | Cipla Ltd. | Crystalline levosalbutamol sulphate (Form II) |
| GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| MX2010001302A (es) | 2007-08-02 | 2010-03-01 | Sigma Tau Ind Farmaceuti | Avidina oxidada con tiempo de residencia elevado en tejidos tratados. |
| EP2106806A1 (en) * | 2008-03-31 | 2009-10-07 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Nanoparticles for targeted delivery of active agents to the lung |
| TW201031436A (en) * | 2009-02-16 | 2010-09-01 | Univ Nat Taiwan | Pharmaceutical composition for inhalation delivery and fabrication method thereof |
-
2012
- 2012-07-25 PH PH1/2014/500193A patent/PH12014500193A1/en unknown
- 2012-07-25 DK DK12740137.0T patent/DK2739314T3/da active
- 2012-07-25 ES ES12740137T patent/ES2729549T3/es active Active
- 2012-07-25 EP EP12740137.0A patent/EP2739314B1/en active Active
- 2012-07-25 PL PL12740137T patent/PL2739314T3/pl unknown
- 2012-07-25 KR KR1020147001707A patent/KR101966630B1/ko not_active Expired - Fee Related
- 2012-07-25 US US14/236,445 patent/US9872831B2/en active Active
- 2012-07-25 JP JP2014523289A patent/JP6019118B2/ja active Active
- 2012-07-25 PT PT12740137T patent/PT2739314T/pt unknown
- 2012-07-25 EA EA201490401A patent/EA026453B1/ru not_active IP Right Cessation
- 2012-07-25 MX MX2014001176A patent/MX355177B/es active IP Right Grant
- 2012-07-25 AU AU2012292229A patent/AU2012292229B2/en not_active Ceased
- 2012-07-25 WO PCT/EP2012/064576 patent/WO2013017494A1/en not_active Ceased
- 2012-07-25 CA CA2842276A patent/CA2842276C/en active Active
- 2012-07-25 BR BR112014002593-2A patent/BR112014002593B1/pt not_active IP Right Cessation
- 2012-07-25 UA UAA201402021A patent/UA114482C2/uk unknown
- 2012-07-25 CN CN201280037217.9A patent/CN103717239B/zh active Active
-
2014
- 2014-01-22 IL IL230597A patent/IL230597A0/en active IP Right Grant
- 2014-02-27 ZA ZA2014/01921A patent/ZA201401921B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014002593A2 (pt) | 2017-03-01 |
| KR20140047668A (ko) | 2014-04-22 |
| BR112014002593B1 (pt) | 2022-11-29 |
| ES2729549T3 (es) | 2019-11-04 |
| CN103717239A (zh) | 2014-04-09 |
| PH12014500193A1 (en) | 2014-03-24 |
| UA114482C2 (uk) | 2017-06-26 |
| EP2739314A1 (en) | 2014-06-11 |
| DK2739314T3 (da) | 2019-06-24 |
| CA2842276C (en) | 2020-11-24 |
| MX2014001176A (es) | 2014-07-14 |
| EA201490401A1 (ru) | 2014-05-30 |
| CN103717239B (zh) | 2017-08-01 |
| JP2014521675A (ja) | 2014-08-28 |
| KR101966630B1 (ko) | 2019-04-09 |
| AU2012292229B2 (en) | 2017-08-03 |
| ZA201401921B (en) | 2015-05-27 |
| PL2739314T3 (pl) | 2019-09-30 |
| PT2739314T (pt) | 2019-06-21 |
| JP6019118B2 (ja) | 2016-11-02 |
| NZ620202A (en) | 2016-05-27 |
| WO2013017494A1 (en) | 2013-02-07 |
| EA026453B1 (ru) | 2017-04-28 |
| CA2842276A1 (en) | 2013-02-07 |
| AU2012292229A1 (en) | 2014-02-13 |
| US20140134106A1 (en) | 2014-05-15 |
| IL230597A0 (en) | 2014-03-31 |
| US9872831B2 (en) | 2018-01-23 |
| EP2739314B1 (en) | 2019-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX349004B (es) | Nuevos compuestos. | |
| IN2014MN00986A (enExample) | ||
| EA201400591A1 (ru) | Ингалятор | |
| CY1117372T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους | |
| GB201118656D0 (en) | New compounds | |
| EA201400392A1 (ru) | ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb | |
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| GB201209613D0 (en) | New compounds | |
| PH12013501842A1 (en) | Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor | |
| IN2014DN00288A (enExample) | ||
| IN2014DN00286A (enExample) | ||
| PL2444081T3 (pl) | Kompozycja do leczenia chorób zapalnych, zawierająca kwas bosweliowy i kannabidiol | |
| IN2014MN01378A (enExample) | ||
| PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| EA201500365A1 (ru) | Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака | |
| TN2014000185A1 (en) | Polyethylene glycol based prodrug of adrenomedullin and use thereof | |
| BR112013022052A2 (pt) | ligantes antagonísticos de dr3 | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| WO2012125408A8 (en) | Pegylated apelin and uses thereof | |
| MX2014006136A (es) | Uso de aril- y hetarilcarboxamidas como endoparasiticidas. | |
| MX370253B (es) | Composiciones de compuestos de jasmonato y métodos de uso de las mismas. | |
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
| MX2013015347A (es) | Terapia direccionada al receptor del factor de crecimiento epidermico (egfr). | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: ALFASIGMA S.P.A. |
|
| FG | Grant or registration |